Full Text
PAR14 COST MINIMIZATION ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB AND ETANERCEPT FOR RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL

Abstract

Authors

MG Saggia EA Santos V Nasciben

Back to Volume 10, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×